COST-EFFECTIVENESS OF REPLACING THE SEQUENCE PCV13/PPV23 WITH PCV20 IN THE FRENCH ADULT PNEUMOCOCCAL VACCINATION PROGRAM

被引：0
|
作者：
Fievez, S. [1 ]
Blanc, E. [1 ]
Bougeois, M. [1 ]
Sivignon, M. [2 ]
Supiot, R. [3 ]
Vietri, J. [4 ]
Perdrizet, J. [4 ]
Bellier, L. [3 ]
机构：
[1] Pfizer SAS France, Paris, France
[2] Putnam PHMR, Lyon, France
[3] Putnam PHMR, Paris, France
[4] Pfizer Inc, Collegeville, PA USA
来源：
VALUE IN HEALTH | 2023年 / 26卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE143
引用
收藏
页码：S78 / S78
页数：1
相关论文
共 50 条
  • [41] A cost-effectiveness analysis of PHiD-CV compared to PCV13 in a national immunization program setting in Tunisia
    Lagoubi, Youness
    Sfar, Mohamed Tahar
    Gomez, Jorge A.
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2022, 18 (05)
  • [42] Response to article by Johnna Perdrizet et al.,"Cost-effectiveness analysis of replacing the 10-valent pneumococcal conjugate vaccine (PCV10) with the 13-valent pneumococcal conjugate vaccine (PCV13) in Brazil infants"
    Gomez, Jorge A.
    Pinto, Thatiana de Jesus Pereira
    Guevara, Javier Nieto
    Noronha, Tatiana Guimaraes de
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2022, 18 (01)
  • [43] Cost-Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Versus Lower-Valent Alternatives in Filipino Infants
    Perdrizet, Johnna
    Horn, Emily K.
    Nua, Winniefer
    Perez-Peralta, Judith
    Nailes, Jennifer
    Santos, Jaime
    Ong-Lim, Anna
    INFECTIOUS DISEASES AND THERAPY, 2021, 10 (04) : 2625 - 2642
  • [44] Cost-Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Versus Lower-Valent Alternatives in Filipino Infants
    Rajeev Dhere
    Vistasp Sethna
    Hitesh Malviya
    Rajeshwari Adhiseshan
    Infectious Diseases and Therapy, 2022, 11 : 1297 - 1299
  • [45] Cost-Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Versus Lower-Valent Alternatives in Filipino Infants
    Dhere, Rajeev
    Sethna, Vistasp
    Malviya, Hitesh
    Adhiseshan, Rajeshwari
    INFECTIOUS DISEASES AND THERAPY, 2022, 11 (03) : 1297 - 1299
  • [46] Cost-Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Versus Lower-Valent Alternatives in Filipino Infants
    Johnna Perdrizet
    Emily K. Horn
    Winniefer Nua
    Judith Perez-Peralta
    Jennifer Nailes
    Jaime Santos
    Anna Ong-Lim
    Infectious Diseases and Therapy, 2021, 10 : 2625 - 2642
  • [47] MODELLING BUDGET IMPACT (BI) OF VACCINATING AT-RISK ADULTS AND THE ELDERLY WITH 23-VALENT PNEUMOCOCCAL POLYSACCHARIDE VACCINE (PPV23) COMPARED TO 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE (PCV13) IN GERMANY
    Jiang, Y.
    Gauthier, A.
    Annemans, L.
    van der Linden, M.
    Nicolas-Spony, L.
    Bresse, X.
    VALUE IN HEALTH, 2011, 14 (07) : A268 - A268
  • [48] Cost-effectiveness and budget impact analysis of PPV23 vaccination for the Malaysian Hajj pilgrims
    Aminuddin, Farhana
    Zaimi, Nur Amalina
    Kunusagaran, Mohd Shaiful Jefri Mohd Nor Sham
    Bahari, Mohd Shahri
    Hassan, Nor Zam Azihan Mohd
    PLOS ONE, 2022, 17 (01):
  • [49] COST MINIMIZATION COMPARISON OF A VACCINATION WITH CAMPAIGN PROGRAM FOR CORPORATIONS USING PCV13 VESUS FREE PCV10 WITH PAID CAMPAIGN
    Fujii, R. K.
    Mould, J.
    Roberts, C. S.
    Presa, J.
    Jardim, E.
    VALUE IN HEALTH, 2012, 15 (07) : A397 - A397
  • [50] RAPID ADOPTION OF PNEUMOCOCCAL 20-VALENT CONJUGATE VACCINE (PCV20) VACCINATION IN ADULT PATIENTS WITH INFLAMMATORY BOWEL DISEASE
    Karime, Christian
    Crosby, Sheena K.
    Bhat, Shubha
    Hashash, Jana G.
    Farraye, Francis A.
    GASTROENTEROLOGY, 2023, 164 (06) : S678 - S679
12345